You are here



CMS released the 2018 Medicare Inpatient Prospective Payment System (IPPS) proposed rule on April 14, promising “transparency, flexibility, program simplification and innovation to transform the Medicare program” in the first IPPS rule under a new CMS and HHS administration.

CMS has issued its final rule aimed at stabilizing the Affordable Care Act (ACA) health insurance exchanges, checking many items off insurers’ wish lists while leaving the most pressing issue—whether cost-sharing reduction subsidies will be funded—unsettled as insurers decided whether to participate in the individual market next year.

Stephen Parente, PhD, MPH, MS, brings a long resume as a health economist and policy expert. He’s spent the last 17 years at the University of Minnesota, currently holding the title of Minnesota Insurance Industry Chair of Health Finance in the Carlson School of Management and director of the school’s Medical Industry Leadership Institute.

The average monthly premium for a benchmark silver-level plan on the Affordable Care Act (ACA) insurance marketplace would need to be increased by 19 percent to compensate for lost cost-sharing subsides if the program isn’t funded by the Republican-controlled Congress for 2018.

While the debate over repealing, replacing or repairing the Affordable Care Act (ACA) is dominating discussion of healthcare policy in Washington these days, the American Hospital Association (AHA) has several other items on its advocacy agenda for 2017. 


Recent Headlines

ACA exchange rules finalized for 2018 as repeal threat looms

CMS hopes to strengthen the risk pool on Affordable Care Act’s insurance marketplace for the 2018 plan year, even as insurers remain uncertain about the exchanges with the incoming Congress and President-elect promising to repeal the law.

5 of the top issues for the healthcare industry in 2017

The annual health issues report from PricewaterhouseCooper’s (PwC) Health Research Institute predicted the coming year will be one of “uncertainty and opportunity” in the industry, both because of the potential repeal of the Affordable Care Act and the continuing transition to value-based care.

Mylan launches generic EpiPen as its sued by 20 states over generics price-fixing

Mylan announced the launch of the authorized generic of its allergic reaction autoinjector treatment, EpiPen. Although the launch fulfilled a promise the pharmaceutical company made months ago, it came only hours after 20 states filed a lawsuit over Mylan’s pricing of other generic drugs. 

52 million with pre-existing conditions could be denied coverage if ACA repealed

If pre-Affordable Care Act (ACA) health insurance regulations returned with a repeal of the law, 52 million people under the age of 65—27 percent of the U.S. population—could be denied coverage on the individual market due to pre-existing conditions.

‘Dramatic slowdown’ in value-based care transition—and how Congress can jumpstart it

Members of the American Medical Group Association (AMGA) reported the transition to value-based care is slower than expected, with more multispecialty medical groups and integrated systems predicting fee-for-service (FFS) payments will take up a greater percentage of revenues in the next few years than originally projected.

$6.3 billion 21st Century Cures Act passes in big win for drug companies, device makers

The U.S. Senate has approved a bill aimed at speeding up regulatory approval for pharmaceuticals and medical devices, as well as providing extra funding for medical research, the Precision Medicine Initiative, and the cancer “moonshot.”

Current ACA repeal plan carries $1.1 trillion increase in uncompensated care costs

The number of uninsured people would more than double and the individual insurance market would collapse if the Affordable Care Act (ACA) is repealed through a fast-track process called budget reconciliation.

CMS reports ‘modest’ 2015 expenditures

A new report from CMS today shows healthcare spending in 2015 was modest compared to years before the Affordable Care Act (ACA) was passed.

6 things to know about AHA’s letter to Trump

The American Hospital Association (AHA) laid out some specific policy priorities for hospitals in a letter to President-elect Donald Trump, offering clues to where their lobbying efforts will focused once Trump takes office.

Reworked '21st Century Cures Act' to get vote in House

A new version of legislation aimed at speeding up regulatory approval for medical devices and drugs will get a vote in the House this week.